摘要:
The present invention relates to inhibitors of 11- β-hydroxysteroid dehydrogenase type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.
摘要:
The present invention is directed to amidinate ligand containing precursors for use in chemical vapor deposition. More particularly, the present invention is directed to amidinate ligand containing precursors such as metalloamidinates as chemical vapor deposition precursors. Suitable precursors for chemical vapor deposition such as atmospheric pressure chemical vapor deposition (APCVD) of films of metals, metal oxides, and metal nitrides, in which the physical properties of the precursors (or films) may be controlled by modification of the precursor ligand array are provided.
摘要:
Die vorliegende Erfindung betrifft ein neues Verfahren zur Herstellung von Ν,Ν' -unsubstituierten Carboxamidinen oder einem Salz hiervon. Des Weiteren betrifft die vorliegende Erfindung ein neues Verfahren zur Herstellung von N, N' -unsubstituierten Carboxamidinen, in dem eine Carboxamidingruppe in einem Schritt in eine gegebene Grundstruktur eingeführt wird.
摘要:
The present invention provides compounds and compound libraries that are useful as protease modulators. The compounds and compound libraries are preferably made using the methods of the present invention which utilize peptide synthesis and combinatorial chemistry methods on a solid phase.
摘要:
The invention relates to inhibitors of sphingosine kinase enzymatic activity, compounds and pharmaceutical compositions that inhibit sphingosine kinase 1 and sphingosine kinase 2 (SphK1 & SphK2) enzymes and further relates to methods of treating diseases and disorders mediated by sphingosine 1 phosphate activity, comprising administering an effective amount of sphingosine kinase inhibitors.
摘要:
The present invention relates to a class of compounds represented by Formula (I), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula (I), and methods of selectively inhibiting or antagonizing the alpha v beta 3 integrin.
摘要:
Compounds of formula (I) and their salts in which R1 is optionally substituted phenyl, R2 is alkyl, cycloalkyl or optionally substituted amino, or R2 and R3 together with the nitrogen and carbon atoms to which they are attached form an optionally substituted heterocyclic ring or R3 and R4 together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic ring and R5 is H, halo, alkyl, alkoxy, trifluoromethyl or a group of formula S(O)mR8 in which m is 0, 1 or 2 and R8 is alkyl have utility in the treatment of diabetes particularly in the treatment of hyperglycaemia.
摘要翻译:式(I)化合物及其盐,其中R 1为任选取代的苯基,R 2为烷基,环烷基或任选取代的氨基,或R 2和R 3与它们所连接的氮和碳原子一起形成任选取代的杂环或 R3和R4与它们所连接的氮原子一起形成任选取代的杂环,R 5是H,卤素,烷基,烷氧基,三氟甲基或式S(O)m R 8基团,其中m是0,1或2 R8是烷基,可用于治疗糖尿病,特别是治疗高血糖症。
摘要:
The invention relates to inhibitors of sphingosine kinase enzymatic activity, compounds and pharmaceutical compositions that inhibit sphingosine kinase 1 and sphingosine kinase 2 (SphK1 & SphK2) enzymes and further relates to methods of treating diseases and disorders mediated by sphingosine 1 phosphate activity, comprising administering an effective amount of sphingosine kinase inhibitors.
摘要:
The present invention relates to inhibitors of 11- ß-hydroxysteroid dehydrogenase type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.